Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma
The objective of this study is to assess the efficacy and safety of TLN-232 used to treat patients with metastatic melanoma that recur/progress after receiving first line systemic therapy.
Melanoma
DRUG: TLN-232
To assess the efficacy of TLN-232 in patients with recurrent metastatic melanoma measured by overall response rate at 16 weeks from date of initial infusion of TLN-232 (Day 1, Cycle 1)., Complete response, partial response or stable disease at 16 weeks from date of initial infusion of TLN-232 (Day 1, Cycle 1)
To examine the safety and tolerability of TLN-232 in patients with recurrent metastatic melanoma, Maximum 13 months from date of initial infusion of TLN-232 (Day 1, Cycle 1)
The objective of this study is to assess the efficacy and safety of TLN-232 used to treat patients with metastatic melanoma that recur/progress after receiving first line systemic therapy.